Articles by Catherine Kolonko

Latest Articles

Hepatitis C Genotype Makes a Difference in Liver Disease, Study Shows
  |  Catherine Kolonko
Patients with hepatitis C genotype 3 may face more liver problems.
Hepatitis C Reinfection Isn't All That Uncommon in Patients with HIV
  |  Catherine Kolonko
Hepatitis C reinfection rates appear to be higher within certain populations.
Phase 3 Trial Reveals High Hepatitis C Success Rate with Investigational Drug
  |  Catherine Kolonko
Glecaprevir/pibrentasvir had a 99% SVR rate in a Japanese population.
Clinical Transplantation Trial Tests Use of Hepatitis C-Infected Kidney
  |  Catherine Kolonko
The Penn Medicine clinical trial uses kidneys from deceased donors who were infected with the hepatitis C virus. The first person in the trial received a kidney transplant in July and then underwent treatment with a regimen of Zepatier, one of the direct acting antiviral drugs approved recently to treat the virus.
VA Finds Success with Various Hepatitis C Regimens for Veterans
  |  Catherine Kolonko
The US Department of Veteran Affairs is finding success with modern DAAs.
High Frequency of Tregs After Curing Hepatitis C Could Enhance Liver Cancer Risk
  |  Catherine Kolonko
Even after eradicating hepatitis C with direct-acting antivirals, high frequency of Tregs could pose complications.
Court Orders Gilead to Pay Merck in Hepatitis C Drug Patent Lawsuit
  |  Catherine Kolonko
Merck just got $2.54 billion richer with the ruling of a federal jury.
Multi-Genotype Hepatitis C Drug Application Lands in Front of the FDA
  |  Catherine Kolonko
An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.
Head-to-Head Comparison of Two Hepatitis C Regimens Reveals Superior
  |  Catherine Kolonko
Elbasvir/grazoprevir (Zepatier) and sofosbuvir (Sovaldi) are used to treat hepatitis C around the world, but is one better than the other?

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$